Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMI vaccine and IL-2 for metastatic breast cancer
NCT00784524Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2008
- Primary completion
- Jul 2014
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic large multivalent immunogen breast cancer vaccine in breast cancer, sponsored by Masonic Cancer Center. Started Sep 2008; status: terminated.
02
Drugs
allogeneic large multivalent immunogen breast cancer vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00784524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784524.